drugset

drugset / Trial / NCT00526812

A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas

NCT00526812 ↗

Phase 1 Completed 54 enrolled Biogen

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study assesses the tolerability, safety, efficacy and pharmacokinetics of RTA 744 in recurrent high-grade gliomas.

Timeline

Start: 2005-11-30
Primary completion: 2008-12-01
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Berubicin	Small molecule	—	Intravenous

Indications